• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Ruxolitinib Phosphate
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    Jakavi
    Novartis
    RX
    partial basket chart
    Jakavi

    Tyrosine Kinase Inhibitor. Ruxolitinib Phosphate 5 mg, 10 mg, 15 mg, 20 mg.
    TAB: blist.: 56, bottle.: 60×5, 15, 20mg
    Start. dose:
    MF: The recomm. start. dose: in is 15
    mg ×2/d for pts. with a plat. count
    between 100,000/mm³ and 200,000/
    mm 3 and 20 mg ×2/d for pts. with a
    plat. count of >200,000/mm³.
    PV: The recomm. start. dose of is 10
    mg×2/d.
    Limited inform. to recommend a start.
    dose for pts. with plat. count. between
    50,000/mm³ & <100,000/mm³.
    The max. recomm. start. dose in these
    pts. is 5 mg ×2/d and the pts. should be
    titrated cautious.
    Dose modific.: Doses may be titrat. based on safety & efficacy. Tmt. should be discont. for plat. counts less than 50,000/mm³ or absolute neutrophil counts less than 500/mm³. In PV, tmt. should also be interrupt. when haemoglobin is below
    8 g/dl. After recov. of blood count. above these levels, dosing may be re-started at 5 mg ×2/d and gradual. incr. based on careful. See. lit.
    Myelofibrosis (MF).: Tmt. of dis.-related splenomeg.or sympt. in adult pts. with prim. MF (also known as chron. idiopath. MF), post polycythaem. vera myelofibrosis or post essential thrombocythaem. MF.
    Polycythaem. vera (PV).: Tmt. of adult pts. with PV who are resist. to or intolerant of hydroxyurea.
    C/I: Hypersens. Preg. Lact.

    CLOSE